TargetBeta
CARD11
caspase recruitment domain family member 11 · also CARMA1, BIMP3 · Membrane associated guanylate kinases
2 programs in company-led studies act on CARD11, from 2 companies: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Autologous Anti-DLL3 CAR/CARD11-PIK3R3 Fusion Transgene-expressing T-cells ML261rule | Moonlight Bio | phase 1 | 11 running | DLL3, PIK3R3 | NCIt |
| CARD11-BCL10-MALT1 Complex Inhibitor XL114rule | Dr. Reddy's Laboratories | phase 1 | 20 running | BCL10, MALT1 | NCIt |
Conditions their studies are in
- Lymphoma, Mantle-Cell, 1 program
- Small Cell Lung Carcinoma, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Mar 2028Autologous Anti-DLL3 CAR/CARD11-PIK3R3 Fusion Transgene-expressing T-cells ML261 · Moonlight Bio · phase 1 · NCT07488923
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.